Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Chemotherapy. Churchill Hospital, Oxford, United Kingdom

Survival: 7.7 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: United Kingdom
City/State/Province: Oxford
Hospital: Churchill Hospital
Journal: Link
Date: 6/2007

Patients: This phase III study involved one hundred and four patients with cutaneous melanoma or unknown primary melanoma with metastases. They were randomly divided into two groups of 52 patients each. The median age was 56 in one group and 57 in the other, ranging from 21-82 years of age.

Treatment: One group of patients was treated with temozolomide alone and the other with temozolomide and lomeguatrib. Both of these are chemotherapy drugs.

Toxicity: Four patients died while on the treatment, but not because of the treatment. All of the patients experienced some sort of toxicity. Patients taking two drugs had more grade 3 and grade 4 toxicities than those on only temozolomide. Grade 3 and 4 toxicities included thrombocytopenia, neutropenia, febrile neutropenia, anemia, vomiting, and nausea.

Results: The median overall survival was 7.7 months for patients taking lomeguatrib and temozolomide, and 7.6 months for those taking temozolomide alone.

Support: This study was supported by Kudos Pharmaceuticals, which is owned by AstraZeneca. This company developed lomeguatrib and provided the drug used in this study.

Correspondence: Dr. Mark R. Middleton

E-mail to a Friend Email Physician More Information